This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The risk factors for postoperative embolism included Black race, interstitial fibrosis, advanced-stage disease requiring bilobectomy or pneumonectomy, and increased operative duration. occurrence of postoperative PE in patients undergoing a first-time pulmonary resection for lung cancer. occurrence of postoperative VTE and a 1.3%
Anthos LILAC trial is focused on preventing stroke and systemic embolism in AFib patients, while ASTER and MAGNOLIA aim to use abelacimab to address VTE and GI cancer. Novartis abelacimab efforts will now take a unique clinical approach since the Anthos-designed phase 3 trials focus on more than just ischemic stroke.
Pulmonary embolism (PE), a form of venous thromboembolism, is a frequently observed complication in malignancies, with a notably high incidence in individuals with lung cancer. The presence of PE markedly redu.
Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25
Among patients with low-risk pulmonary embolism, 18 months of anticoagulation significantly reduced its recurrence, compared with 6 months of treatment.
We herein present a rare upper extremity PCD case accompanied with supra vena cava and pulmonary embolism in a cervical cancer patient, who presented to our institution with severe pain, edema and irreversible venous gangrene of right upper limb with no response to anticoagulation therapy.
It has been shown that patients with cancer have a longer expected life duration, benefiting from advanced medical therapy. A growing number of studies have elucidated the association between cancer and CVD. Moreover, different types of cancer have distinct risks, which may increase the complexity of antithrombotic therapy.
Cancer patients have a higher risk of atrial fibrillation (AF) than general population, however, the link between cancer and AF is not fully understood. The association between AF detected by implanted cardiac implantable electronic devices (CIEDs) and the incidence of embolic stroke has been reported.
Background Data on the management of patients with cancer presenting with sudden cardiac arrest (SCA) are scarce. We aimed to assess the characteristics and outcomes of SCA according to cancer history. Results Out of 4069 patients who had SCA admitted alive in hospital, 207 (5.1%) had current or past medical history of cancer.
Addressing the serious issue of delayed and missed findings in diagnostic imaging, CINA-iPE is an AI-powered tool that detects incidental pulmonary embolism during routine CT scans. This is particularly relevant in the cancer patient population, where pulmonary embolism is a significant cause of mortality.
However, there are no existing data supporting an independent relationship between cancer and atrial cardiopathy, another atrial pathology associated with increased acute ischemic stroke (AIS) risk. The study exposure was active cancer. We performed a subgroup analysis among patients with embolic stroke of undetermined source (ESUS).Results:The
BackgroundThe risk of comorbidity of cancer is increased in atrial fibrillation (AF) patients, which is a massive challenge for clinical management in cardiovascular settings. The propensity score matching method was utilized to balance the differences between the cancer and non-cancer groups. 1.83, P = 0.62).ConclusionsThe
However, the relationship between cancer and stroke is not well studied. Previous research in this area suggests presence of right-to-left shunt as a possible underlying mechanism of paradoxical embolism in patients with cancer diagnosis within one year of the stroke.
An 84-year-old male with a history of prostate cancer not on chemotherapy presented to the ED with complaints of shortness of breath worse on exertion ongoing for 1 week accompanied by generalized malaise. this clinical case, we discussed sub-massive pulmonary embolism (PE) complicated by a right heart clot-in-transit presenting insidiously.
Abelacimab is currently in Phase 3 development with the lead indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.
We aimed to compare IS characteristics of patients with non-small cell lung cancer (NSCLC) who received ICIs compared to those who did not. Stroke etiology consistent with embolic stroke with unknown source (ESUS) was more common in the ICI group (chemotherapy only 2.3%, ICI 64%, p=0.02).Conclusions:Contrary
Family: Diabetes mellitus, gastric cancer, COVID. We catheterized ophthalmic artery, and did embolization through it, with a successful result, and with no ophthalmic symptoms after embolization.ConclusionDural arteriovenous fistulas are shunts found from dural vessels. Male, 46 years old, electric worker, right‐handed.
Often caused by sudden interruption of blood flow to the spinal cord due to embolic phenomena, intrinsic factors such as connective tissue disease, and due to intra/post‐operative hypotension leading to ischemia or infarction. IntroductionSpinal cord infarctions (SCI) are scarce entities, constituting only 0.3‐1%
Anand Swaminathan on a simple approach to status epilepticus, David Juurlink on codeine and tramadol interactions: nasty drugs with nastier drug interactions, Brit Long on DOACS in patients with malignancy: which patient's with cancer can be safely prescribed DOACs?
BackgroundNew treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status.
The role of paradoxical embolization as a stroke etiology in patients with cancer is uncertain. Our study investigated the relationship between cancer-related stroke and the presence of a patent foramen ovale (PFO).Methods:We years, female sex 36.4%), 103 (4.6%) had active cancer, of whom 24 (23%) were diagnosed with PFO.
Subsequent investigations revealed pulmonary embolism, deep vein thrombosis, and imaging findings suggestive of pancreatic cancer. Following PCI, she was treated with optimal medical therapy, including dual antiplatelet therapy. Anticoagulation therapy was initiated to manage the VTE.
The primary treatment modalities entail surgical intervention or embolization followed by surgery. Advancements in comprehending the molecular pathways underlying AVMs have sparked interest in repurposing targeted therapies initially devised for cancer treatment.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content